RHIZEN-PHARMACEUTICALS
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct acting anti-viral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19 ”.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit www.rhizen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Helical Fusion Signs Japan’s First Power Purchase Agreement for Fusion Energy with Aoki Super8.12.2025 10:00:00 CET | Press release
Agreement signals growing market demand for stable, continuous, net-electricity fusion power based on the Helical Stellarator Helical Fusion Co., Ltd. (Headquarters: Tokyo, Japan; “Helical Fusion”), a company developing a commercially viable Helical Stellarator power plant under its “Helix Program”, has signed a Power Purchase Agreement (PPA) with Aoki Super Co., Ltd. (Headquarters: Aichi, Japan; “Aoki Super”), a major regional supermarket chain in central Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207372064/en/ Takaya Taguchi (left), CEO of Helical Fusion Co., Ltd. , and Masayuki Kono (right) Managing Director and Head of Administration Division of Aoki Super Co., Ltd. at the press conference held on December 8, 2025 This marks the first fusion-energy PPA ever signed in Japan, representing a concrete step forward in the real-world adoption of fusion energy and signaling growing demand-side engagement in the em
Tecnotree Mentioned in Various 2025 Gartner® Research8.12.2025 09:41:00 CET | Press release
Tecnotree is a 5G-ready digital Business Support System (BSS) provider with advanced AI/ML capabilities and multi-cloud extensibility. The company has been listed across thirteen 2025 Gartner research spanning Digital BSS, AI-driven monetization, digital marketplace enablement, and customer experience transformation. We believe these mentions reflects the continued relevance and strong applicability of Tecnotree’s solutions within the technology domains evaluated by Gartner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208688494/en/ Tecnotree Mentioned in Various 2025 Gartner® Research The research span Market Guides, Hype Cycles, Magic Quadrants, Critical Capabilities, and Competitive Landscape reports, which we think collectively provides an overview of how various technologies are evolving across the communications ecosystem. We believe that Tecnotree’s appearance across these research categories underscores what we
AI Won't Transform Mobility Without Unprecedented Collaboration, Study Reveals8.12.2025 09:25:00 CET | Press release
First comprehensive analysis of real-world AI applications exposes critical gap between technology's promise and scaled deployment, according to the MIT Mobility Initiative and Kearney Advanced Mobility Institute Artificial intelligence is quietly reshaping global transportation systems, but most deployments remain isolated pilots that haven't achieved scale – and the gap between AI's promise and its execution is widening, according to a landmark study launched today at CoMotion GLOBAL in Riyadh. The Envisioning the Future of Mobility Powered by AI report, developed by the MIT Mobility Initiative and Kearney Advanced Mobility Institute, analyzed input from 55 leading global organizations, including Google, Lyft, Uber Freight, Deutsche Bahn, and NEOM. The study mapped real-world AI applications across mobility systems in Europe, the Americas, APAC, and the Middle East – revealing both breakthrough potential and fundamental challenges in bringing AI-powered mobility to scale. The report
ATEC2025·Real-World Extreme Challenge Concludes with Zhejiang University Team Claiming $150,000 Prize for Breakthrough in Fully Autonomous Robotics8.12.2025 09:25:00 CET | Press release
Thirteen global teams push the boundaries of “no remote control” robotics, driving the evolution from teleoperated tools to autonomous agents The ATEC2025·Real-World Extreme Challenge successfully concluded on December 7 on the campus of The Chinese University of Hong Kong. A team from Zhejiang University emerged victorious from a field of 13 talented international squads by demonstrating exceptional fully autonomous embodied intelligence, securing the top prize of $150,000 USD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207877880/en/ A Zhejiang University team wins ATEC2025·Real-World Extreme Challenge Organized by the Chinese University of Hong Kong and co-hosted by Advanced Technology Exploration Community (ATEC), Peking University, Beijing Normal University, and Ant Group, ATEC2025·Real-World Extreme Challenge was the world’s first intelligent robotics challenge held entirely outdoors on natural terrain—featuring
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release
SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom